English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/139331
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

HisAK70: Progress towards a vaccine against different forms of leishmaniosis

AutorDomínguez-Bernal, Gustavo; Horcajo, Pilar; Orden, José A.; Ruiz-Santa-Quiteria, José A.; Fuente, Ricardo de la; Ordóñez-Gutiérrez, Lara ; Martínez-Rodrigo, Abel; Mas, Alicia; Carrión, Javier
Palabras claveLeishmaniosis
Cross-protection
Leishmania major
Leishmania infantum
Hsp70
Granuloma
Kmp11
A2
Vaccine
DNA
Histones
Fecha de publicación2015
EditorBioMed Central
CitaciónParasites and Vectors 8 (2015)
ResumenBackground: Leishmania major and Leishmania infantum are among the main species that are responsible for cutaneous leishmaniosis (CL) and visceral leishmaniosis (VL), respectively. The leishmanioses represent the second-largest parasitic killer in the world after malaria. Recently, we succeeded in generating a plasmid DNA (pCMV-HISA70m2A) and demonstrated that immunized mice were protected against L. major challenge. The efficacy of the DNA-vaccine was further enhanced by the inclusion of KMP-11 antigen into the antibiotic-free plasmid pVAX1-asd. Methods: Here, we describe the use of a HisAK70 DNA-vaccine encoding seven Leishmania genes (H2A, H2B, H3, H4, A2, KMP11 and HSP70) for vaccination of mice to assess the induction of a resistant phenotype against VL and CL. Results: HisAK70 was successful in vaccinated mice, resulting in a high amount of efficient sterile hepatic granulomas associated with a hepatic parasite burden fully resolved in the VL model; and resulting in 100 % inhibition of parasite visceralization in the CL model. Conclusions: The results suggest that immunization with the HisAK70 DNA-vaccine may provide a rapid, suitable, and efficient vaccination strategy to confer cross-protective immunity against VL and CL.
URIhttp://hdl.handle.net/10261/139331
DOI10.1186/s13071-015-1246-y
Identificadoresdoi: 10.1186/s13071-015-1246-y
issn: 1756-3305
Aparece en las colecciones: (CBM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
HisAK70-ProgressTowardsAVaccine.pdf1,43 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.